Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

Published	Pages	Publisher	Report code
Dec 2021	58	Global Markets Direct	ASDR-595777

Published: Dec 2021 - Pages : 58 - Publisher : Global Markets Direct - Report code : ASDR-595777

Allysta Pharmaceuticals Inc
Amryt Pharma Plc
Arrevus Inc
Astellas Pharma Inc
Cellivery Therapeutics Inc
Jyant Technologies Inc
NeuroNano Pharma Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

This report can be of interest as well:

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

Published: December, 2022 | Report code: ASDR-613965

Mark your calendar:

Veterans Affairs Healthcare Summit

23 July - 24 July, 2024
Arlington, United States